Prognostic Markers in Prostate Cancer
| Period from: | 2008-10-01 to 2009-09-30 |
| Principal Investigators: | Dr. F. Saad |
| Co-Investigators: | Anne-Marie Mes-Masson; Pierre Karakiewicz; Armen Aprikian; Louis Bégin |
| Institution: | Centre Hospitalier de l'Universite de Montréal |
| Department: | Urology |
| Partner: | Canadian Partnership Against Cancer Corporation |
| Program: | Biomarker Pilot Research Project |
| Abstract: |
The main goal of this project is to identify molecular markers that will contribute to improving presently available tools for decision making at every stage of the prostate cancer. The investigation will have two specific objectives:
- To develop a multiparametric test on prostate biopsy to help stratify patients with apparently low-stage/low risk disease that might evolve into a life-threatening disease from those that are the least likely to progress and could be safely put on a surveillance protocol and avoid the risks of therapy.
- To characterize a set of prognostic markers on radical prostatectomy specimens that will add to the currently used clinical and pathological parameters, to identify patients at high-risk of cancer recurrence and or progression that may benefit from adjuvant or neo-adjuvant therapies.
Data from both approaches will be combined within nomograms, along with age, co-morbidity profile as well as clinical and pathological characteristics, to more accurately risk stratify the host-adjusted, individual risk-characteristics of each prostate cancer.
|
| Funding Information: | |
| 2008-2009 | $86,000 |
| 2009-2010 | $86,000 |
| TOTAL | $172,000 |
|
 |
